Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $22.57.
Several research firms have commented on VIR. HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Vir Biotechnology in a research note on Monday, November 9th. Needham & Company LLC upped their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Wall Street Zen raised shares of Vir Biotechnology from a "hold" rating to a "buy" rating in a report on Saturday, November 7th. Zacks Research raised shares of Vir Biotechnology from a "strong sell" rating to a "hold" rating in a research note on Wednesday, November 4th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Vir Biotechnology in a research report on Friday, October 2nd.
Get Our Latest Report on VIR
Insider Buying and Selling at Vir Biotechnology
In related news, EVP Vanina de Verneuil sold 2,407 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total transaction of $26,717.70. Following the completion of the sale, the executive vice president directly owned 110,193 shares in the company, valued at $1,223,142.30. This represents a 2.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.90% of the company's stock.
Institutional Trading of Vir Biotechnology
Several hedge funds and other institutional investors have recently bought and sold shares of VIR. BlackRock Inc. purchased a new position in shares of Vir Biotechnology in the second quarter worth $210,712,000. ARCH Venture Management LLC purchased a new stake in Vir Biotechnology during the 2nd quarter valued at $129,353,521. ADAR1 Capital Management LLC bought a new stake in Vir Biotechnology in the 1st quarter worth $24,593,000. Dimensional Fund Advisors LP grew its holdings in Vir Biotechnology by 1.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,579,678 shares of the company's stock worth $23,107,000 after acquiring an additional 43,401 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in Vir Biotechnology in the 2nd quarter worth $11,642,000. Institutional investors own 65.32% of the company's stock.
Vir Biotechnology Stock Performance
Shares of NASDAQ:VIR opened at $9.15 on Thursday. Vir Biotechnology has a 52-week low of $5.32 and a 52-week high of $14.38. The firm has a fifty day moving average of $11.04 and a 200 day moving average of $9.77. The firm has a market capitalization of $1.57 billion, a PE ratio of -7.26 and a beta of 1.70.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.57) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.18. The firm had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.98 million. The firm's revenue was down 178.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.17) EPS. On average, sell-side analysts forecast that Vir Biotechnology will post -1.28 EPS for the current fiscal year.
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company's pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.